Immunogenicity of cholera vaccination in children with inflammatory bowel disease

References

• Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and ulcerative colitis associations (EFCCA) patient survey. J Crohns Colitis. 2007;1(1):10–20. doi:10.1016/j.crohns.2007.06.005.
   PubMed Web of Science ®Google Scholar
• Larsson K, Lööf L, Rönnblom A, Nordin K. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res. 2008;64(2):139–48. doi:10.1016/j.jpsychores.2007.10.007.
   PubMed Web of Science ®Google Scholar
• Habibi F, Habibi ME, Gharavinia A, Mahdavi S, Akbarpour M, Baghaei A, Emami M. Quality of life in inflammatory bowel disease patients: a cross-sectional study. J Res Med Sci. 2017;22:104. doi:10.4103/jrms.JRMS_975_16.
   PubMed Web of Science ®Google Scholar
• Steffen R. Epidemiology of traveler’s diarrhea. Clin Infect Dis. 2005;41:S536‐S540.
   Web of Science ®Google Scholar
• GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459‐1544.
   Web of Science ®Google Scholar
• Ellul P, Fenech VA, Azzopardi C, Callus L, Delicata N, Muscat J, Azzopardi N, Vassallo M. Diarrhoeal episodes in travellers suffering from IBD. Frontline Gastroenterol. 2013;4(2):120–24.
   PubMedGoogle Scholar
• Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn’s and colitis organization and European society of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257‐291.
   Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J, Barabino A, Braegger CP, Bronsky J. European Crohn's and Colitis Organisation; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8(10):1179‐270.
   Web of Science ®Google Scholar
• Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337‐346.e10.
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Joelson A, Green PHR, Lawlor G, Lichtiger S, Cadwell K, Lebwohl B. Enteric infections are common in patients with flares of inflammatory bowel disease. Am J Gastroenterol. 2018;113(10):1530‐1539. doi:10.1038/s41395-018-0211-8.
   PubMed Web of Science ®Google Scholar
• Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013;4(4):167‐185. doi:10.1177/2040622313485275.
   PubMedGoogle Scholar
• Weinke T, Liebold I, Burchard GD, Frühwein N, Grobusch MP, Hatz C, Kollaritsch H, Nothdurft HD, Reisinger E, Rieke B, et al. Prophylactic immunisation against traveller’s diarrhoea caused by enterotoxin-forming strains of Escherichia coli and against cholera: does it make sense and for whom? Travel Med Infect Dis. 2008;6(6):362‐367. doi:10.1016/j.tmaid.2006.05.003.
   PubMedGoogle Scholar
• Chen WH, Garza J, Choquette M, Hawkins J, Hoeper A, Bernstein DI, Cohen MB. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae. Clin Vaccine Immunol. 2015;22(1):129‐13. doi:10.1128/CVI.00560-14.
   Google Scholar
• Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev. 2013;2013(7):CD009029.
   PubMedGoogle Scholar
• Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62(11):1653‐1664. doi:10.1136/gutjnl-2012-303955.
   PubMed Web of Science ®Google Scholar
• Jonker EFF, Uijlings MAC, Visser LG, Soonawala D. Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate – a controlled trial. Vaccine. 2019;37(23):3133‐3139. doi:10.1016/j.vaccine.2019.04.010.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, G. D, Ehehalt R, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443‐468. doi:10.1016/j.crohns.2013.12.013.
   Web of Science ®Google Scholar
• Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo D, Otley A, LeLeiko NS, Mack D, et al. Appraisal of the pediatric Crohnʼs disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010;105(9):2085–92. doi:10.1038/ajg.2010.143.
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423–32. doi:10.1053/j.gastro.2007.05.029.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42(RR–4):1–18.
   Google Scholar
• Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(7):851–56. doi:10.1016/j.cgh.2007.02.035.
   PubMed Web of Science ®Google Scholar
• Banaszkiewicz A, Targońska B, Kowalska-Duplaga K, Karolewska-Bochenek K, Sieczkowska A, Gawrońska A, Grzybowska-Chlebowczyk U, Krzesiek E, Łazowska-Przeorek I, Kotowska M, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(7):1607–14. doi:10.1097/MIB.0000000000000406.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera Country Profiles. Available at: https://www.who.int/cholera/countries/en. Accessed 3 June 2020.
   Google Scholar
• Human anti-cholera toxin B subunit ELISA kit® instruction manual M-945-110-CTG, Alpha diagnostic international. [accessed 2020 June 28]. https://www.4adi.com.
   Google Scholar
• Saha A, Chowdhury MI, Nazim M, Alam MM, Ahmed T, Hossain MB, Hore SK, Sultana GNN, Svennerholm A-M, Qadri F, et al. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children. Vaccine. 2013;31(4):647–52. doi:10.1016/j.vaccine.2012.11.049.
   PubMed Web of Science ®Google Scholar
• Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine. 2009;27(9):1433–39. doi:10.1016/j.vaccine.2008.12.036.
   PubMed Web of Science ®Google Scholar
• Ł D, Dziekiewicz M, Banaszkiewicz A. Immune response to vaccination in children and young people with inflammatory bowel disease: a systematic review and meta-analysis [published online ahead of print, 2020 Jun 15]. J Pediatr Gastroenterol Nutr. 2020;71(4):423–32. doi:10.1097/MPG.0000000000002810.
   PubMed Web of Science ®Google Scholar
• Li Y, Jin L, Chen T. The effects of secretory IgA in the mucosal immune system. Biomed Res Int. 2020;2020:2032057. Published 2020 Jan 3.
   PubMed Web of Science ®Google Scholar
• Uddin T, Harris JB, Bhuiyan TR, Shirin T, Uddin MI, Khan AI, Chowdhury F, LaRocque RC, Alam NH, Ryan ET, et al. Mucosal immunologic responses in cholera patients in Bangladesh. Clin Vaccine Immunol. 2011;18(3):506–12. doi:10.1128/CVI.00481-10.
   PubMedGoogle Scholar
• Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci. 2015;60(8):2446–53. doi:10.1007/s10620-015-3631-y.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Fadrowski J, Neu A. Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients. Pediatr Nephrol. 2018;33(6):1037–43. doi:10.1007/s00467-017-3878-y.
   PubMed Web of Science ®Google Scholar
• Maritsi DN, Coffin SE, Argyri I, Vartzelis G, Spyridis N, Tsolia MN. Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study. Clin Exp Rheumatol. 2017;35:711–15.
   PubMed Web of Science ®Google Scholar
• Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB, Ryan AL, Cole CH, Richmond PC. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients. Cancer. 2017;123(21):4215–23. doi:10.1002/cncr.30764.
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Shaw P, Mackie FE, Boros C, Marshall H, Barnes M, Seale H, Kennedy SE, Moa A, Hayen A, et al. Immunogenicity and persistence of immunity of a quadrivalent human papillomavirus (HPV) vaccine in immunocompromised children. Vaccine. 2016;34(36):4343–50. doi:10.1016/j.vaccine.2016.06.049.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32:e00084–18.
   PubMed Web of Science ®Google Scholar
• Bishop AL, Camilli A. Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines. 2011;10:79–94.
   PubMed Web of Science ®Google Scholar
• Qadri F, Ryan ET, Faruque AS, Ahmed F, Khan AI, Islam MM, Akramuzzaman SM, Sack DA, Calderwood SB. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun. 2003;71(8):4808–14.
   PubMed Web of Science ®Google Scholar
• Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Kärnell A, Nyquist I, Svennerholm AM. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine. 2007;25(22):4392–400.
   PubMed Web of Science ®Google Scholar
• Qadri F, Akhtar M, Bhuiyan TR, Chowdhury MI, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Lundgren A, et al. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2020;20(2):208–19.
   PubMed Web of Science ®Google Scholar
• Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa. [accessed 2020 Dec 16]. https://scandinavianbiopharma.se/promising-preliminary-findings-from-a-phase-2b-study-of-the-oral-vaccine-etvax-against-travelers-diarrhea-in-finnish-travelers-to-benin-west-africa.
   Google Scholar
• Dukoral® – product characteristics. [accessed 2020 July 04]. https://www.ema.europa.eu/en/documents/product-information/dukoral-epar-product-information_en.pdf.
   Google Scholar
• Sanchez JL, Hayashi KE, Kruger HF, Meza R, English CK, Vidal W, Svennerholm AM, Taylor DN. Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians. Trans R Soc Trop Med Hyg. 1995;89(5):542–45.
   PubMed Web of Science ®Google Scholar
• Baik YO, Choi SK, Olveda RM, Espos RA, Ligsay AD, Montellano MB, Yeam JS, Yang JS, Park JY, Kim DR, et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine. 2015;33(46):6360–65.
   PubMed Web of Science ®Google Scholar
• Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, et al. Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn’s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis. 2014;8(5):384–91.
   PubMed Web of Science ®Google Scholar
• Satyam VR, Li PH, Reich J, Qazi T, Noronha A, Wasan SK, Farraye FA. Safety of recombinant zoster vaccine in patients with inflammatory bowel disease. Dig Dis Sci. 2020;65(10):2986–91. doi:10.1007/s10620-019-06016-4.
   Web of Science ®Google Scholar
• Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, Garcia-Sanchez V, Fries W, van Asseldonk DP, Farkas K, et al. European Crohn's and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60(4):456–62.
   PubMed Web of Science ®Google Scholar